Clinical Trial Update: Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating safety and efficacy of γδ T cell therapy for non-small cell lung cancer without EGFR mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• T-cell therapy

Snippet

Sponsor: Fuda Cancer Hospital, Guangzhou | Conditions: Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED